{"id":"NCT00249795","sponsor":"Sanofi","briefTitle":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","officialTitle":"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2005-11-07","resultsPosted":"2010-10-15","lastUpdate":"2010-10-15"},"enrollment":9016,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Atrial Fibrillation","Cardiovascular Disease"],"interventions":[{"type":"DRUG","name":"Irbesartan","otherNames":["AprovelÂ®"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Irbesartan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular events.","primaryOutcome":{"measure":"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication","timeFrame":"Median follow-up of 4.5 years","effectByArm":[{"arm":"Irbesartan","deltaMin":963,"sd":null},{"arm":"Placebo","deltaMin":963,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8570"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":30,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Italy","Malaysia","Mexico","Netherlands","Norway","Poland","Portugal","Singapore","South Africa","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["21388310"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1409,"n":4518},"commonTop":["Any infections and infestations","Any gastrointestinal disorders","Any nervous system disorders","Any musculoskeletal and connective tissue disorders","Any general disorders and administration site conditions"]}}